Identifi cation of FHL1 as a regulator of skeletal muscle mass: Implications for human myopathy

Journal of Cell Biology

Volumn 183, Issue 6, 2008, Pages 1033-1048

  Cowling, Belinda S ^a   McGrath, Meagan J ^a   Nguyen, Mai Anh ^c   Cottle, Denny L ^a   Kee, Anthony J ^c,d   Brown, Susan ^a   Schessl, Joachim ^b   Zou, Yaqun ^b   Joya, Josephine ^c   Bönnemann, Carsten G ^b   Hardeman, Edna C ^c,d   Mitchell, Christina A ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN'S MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; FHL1 PROTEIN; LIM PROTEIN; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; FHL1 PROTEIN, HUMAN; FHL1 PROTEIN, MOUSE; MUSCLE PROTEIN; NFATC1 PROTEIN, HUMAN; NFATC1 PROTEIN, MOUSE; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR GATA 2;

ANIMAL TISSUE; ARTICLE; CELL FUSION; CELL LINE; CONTROLLED STUDY; CYTOPLASM; FATIGUE; MOUSE; MUSCLE HYPERTROPHY; MUSCLE MASS; MUSCLE STRENGTH; MYOBLAST; MYOPATHY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKELETAL MUSCLE; TRANSGENIC MOUSE; ANIMAL; GENETIC TRANSCRIPTION; GENETICS; HUMAN; HYPERTROPHY; METABOLISM; MUSCLE DISEASE; MUTATION; ORGAN SIZE; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ZIZIPHUS MAURITIANA;

ANIMALS; CALCINEURIN; CELL FUSION; GATA2 TRANSCRIPTION FACTOR; HUMANS; HYPERTROPHY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MUSCLE FIBERS, SKELETAL; MUSCLE PROTEINS; MUSCLE, SKELETAL; MUSCULAR DISEASES; MUTATION; MYOBLASTS; NFATC TRANSCRIPTION FACTORS; ORGAN SIZE; PROTEIN BINDING; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION;

EID: 58249091742     PISSN: 00219525     EISSN: 00219525     Source Type: Journal    
DOI: 10.1083/jcb.200804077     Document Type: Article

References (77)

1. Abbott, K.L., B.B. Friday, D. Thaloor, T.J. Murphy, and G.K. Pavlath. 1998. Activation and cellular localization of the cyclosporine A-sensitive transcription factor NF-AT in skeletal muscle cells. Mol. Biol. Cell. 9:2905-2916.
2. Abmayr, S.M., L. Balagopalan, B.J. Galletta, and S.J. Hong. 2003. Cell and molecular biology of myoblast fusion. Int. Rev. Cytol. 225:33-89.
3. Abramoff, M.D., P.J. Magelhaes, and S.J. Ram. 2004. Image processing with ImageJ. Biophotonics International. 11:36-42.
4. Adams, G.R. 2006. Satellite cell proliferation and skeletal muscle hypertrophy. Appl. Physiol. Nutr. Metab. 31:782-790.
5. Bader , D., T. Masaki, and D.A. Fischman. 1982. Immunochemical analysis of myosin heavy chain during avian myogenesis in vivo and in vitro. J. Cell Biol. 95:763-770.
6. Barton-Davis, E.R., D.I. Shoturma, and H.L. Sweeney. 1999. Contribution of satellite cells to IGF-I induced hypertrophy of skeletal muscle. Acta Physiol. Scand. 167:301-305.
7. Boonyarom, O., and K. Inui. 2006. Atrophy and hypertrophy of skeletal muscles: structural and functional aspects. Acta Physiol (Oxf.). 188:77-89.
8. Brennan, K.J., and E.C. Hardeman. 1993. Quantitative analysis of the human alpha-skeletal actin gene in transgenic mice. J. Biol. Chem. 268:719-725.
9. Brooke, M.H., and H.E. Neville. 1972. Reducing body myopathy. Neurology. 22:829-840.
10. Chakkalakal, J.V., M.A. Harrison, S. Carbonetto, E. Chin, R.N. Michel, and B.J. Jasmin . 2004 . Stimulation of calcineurin signaling attenuates the dystrophic pathology in mdx mice. Hum. Mol. Genet. 13:379-388.
11. Chin, E.R., E.N. Olson, J.A. Richardson, Q. Yang, C. Humphries, J.M. Shelton, H. Wu, W. Zhu, R. Bassel-Duby, and R.S. Williams. 1998. A calcineurindependent transcriptional pathway controls skeletal muscle f ber type. Genes Dev. 12:2499-2509.
12. Cole, F., T.M. Fasy, S.S. Rao, M.A. de Peralta, and D.S. Kohtz. 1993. Growth factors that repress myoblast differentiation sustain phosphorylation of a specif c site on histone H1. J. Biol. Chem. 268:1580-1585.
13. Corbett, M.A., C.S. Robinson, G.F. Dunglison, N. Yang, J.E. Joya, A.W. Stewart, C. Schnell , P.W. Gunning , K.N. North , and E.C. Hardeman . 2001 . A mutation in alpha-tropomyosin(slow) affects muscle strength, maturation and hypertrophy in a mouse model for nemaline myopathy. Hum. Mol. Genet. 10:317-328.
14. Cottle, D.L., M.J. McGrath, B.S. Cowling, ID. Coghill, S. Brown, and C.A. Mitchell . 2007 . FHL3 binds MyoD and negatively regulates myotube formation. J. Cell Sci. 120:1423-1435.
15. Cox, R.D., I. Garner, and M.E. Buckingham. 1990. Transcriptional regulation of actin and myosin genes during differentiation of a mouse muscle cell line. Differentiation. 43:183-191.
16. De Arcangelis, V, D. Coletti, M. Canato, M. Molinaro, S. Adamo, C. Reggiani, and F. Naro. 2005. Hypertrophy and transcriptional regulation induced in myogenic cell line L6-C5 by an increase of extracellular calcium. J. Cell. Physiol. 202:787-795.
17. Delling, U., J. Tureckova, H.W. Lim, LJ. De Windt, P. Rotwein, and J.D. Molkentin. 2000 . A calcineurin-NFATc3-dependent pathway regulates skeletal muscle differentiation and slow myosin heavy-chain expression. Mol. Cell. Biol. 20:6600-6611.
18. Dunn , S.E. , J.L. Burns , and R.N. Michel . 1999 . Calcineurin is required for skeletal muscle hypertrophy. J. Biol. Chem. 274:21908-21912.
19. Erbay, E., I.H. Park, PD. Nuzzi, C.J. Schoenherr, and J. Chen. 2003. IGF-II transcription in skeletal myogenesis is controlled by mTOR and nutrients. J. Cell Biol. 163:931-936.
20. Figarella-Branger, D., G.A. Putzu, C. Bouvier-Labit, J. Pouget, D. Chateau, M. Fardeau, and J.F Pellissier . 1999 . Adult onset reducing body myopathy Neuromuscul. Disord. 9:580-586.
21. Fornaro, M., P.M. Burch, W. Yang, L. Zhang, C.E. Hamilton, J.H. Kim, B.G. Neel, and A.M. Bennett . 2006 . SHP-2 activates signaling of the nuclear factor of activated T cells to promote skeletal muscle growth. J. Cell Biol. 175:87-97.
22. Fortier, M., F Comunale, J. Kucharczak, A. Blangy, S. Charrasse, and C. Gauthier-Rouviere . 2008 . RhoE controls myoblast alignment prior fusion through RhoA and ROCK. Cell Death Differ. 15:1221-1231.
23. Friday , B.B., V. Horsley , and G.K. Pavlath. 2000. Calcineurin activity is required for the initiation of skeletal muscle differentiation. J. Cell Biol. 149:657-666.
24. Furmanczyk, PS., and L.S. Quinn. 2003. Interleukin-15 increases myosin accretion in human skeletal myogenic cultures. Cell Biol. Int. 27:845-851.
25. Gregorevic , P. , D.R. Plant , and G.S. Lynch. 2004. Administration of insulin-like growth factor-I improves fatigue resistance of skeletal muscles from dystrophic mdx mice. Muscle Nerve. 30:295-304.
26. Gunning, P., E. Hardeman, R. Wade, P. Ponte, W. Bains, H.M. Blau, and L. Kedes . 1987 . Differential patterns of transcript accumulation during human myogenesis. Mol. Cell. Biol. 7:4100-4114.
27. Gunther, T., C. Poli, J.M. Muller, P. Catala-Lehnen, T. Schinke, N. Yin, S. Vomstein, M. Amling, and R. Schule. 2005. Fhl2 def ciency results in osteopenia due to decreased activity of osteoblasts. EMBO J. 24:3049-3056.
28. Horsley, V., and G.K. Pavlath. 2002. NFAT: ubiquitous regulator of cell differentiation and adaptation. J. Cell Biol. 156:771-774.
29. Horsley, V., B.B. Friday, S. Matteson, K.M. Kegley, J. Gephart, and G.K. Pavlath. 2001 . Regulation of the growth of multinucleated muscle cells by an NFATC2-dependent pathway. J. Cell Biol. 153:329-338.
30. Ichida, M., and T. Finkel . 2001 . Ras regulates NFAT3 activity in cardiac myocytes. J. Biol. Chem. 276:3524-3530.
31. Johannessen, M., S. Moller, T. Hansen, U. Moens, and M. Van Ghelue. 2006. The multifunctional roles of the four-and-a-half-LIM only protein FHL2. Cell. Mol. Life Sci. 63:268-284.
32. Joya, J.E., A.J. Kee, V. Nair-Shalliker, M. Ghoddusi, M.A. Nguyen, P. Luther, and E.C. Hardeman . 2004 . Muscle weakness in a mouse model of nemaline myopathy can be reversed with exercise and reveals a novel myof ber repair mechanism. Hum. Mol. Genet. 13:2633-2645.
33. Kegley, K.M., J. Gephart, G.L. Warren, and G.K. Pavlath. 2001. Altered primary myogenesis in NFATC3(-/-) mice leads to decreased muscle size in the adult. Dev. Biol. 232:115-126.
34. Kiyomoto, B.H., N. Murakami, Y. Kobayashi, K. Nihei, T. Tanaka, K. Takeshita, and I. Nonaka. 1995. Fatal reducing body myopathy. Ultrastructural and immunohistochemical observations. J. Neurol. Sci. 128:58-65.
35. Knight, P.J., and J.A. Trinick. 1982. Preparation of myofbrils. Methods Enzymol. 85 Pt. B:9-12.
36. Liewluck, T, Y.K Hayashi, M. Ohsawa, R. Kurokawa, M. Fujita, S. Noguchi, I. Nonaka, and I. Nishino. 2007. Unfolded protein response and aggresome formation in hereditary reducing-body myopathy. Muscle Nerve. 35:322-326.
37. Loughna, PT, P. Mason, S. Bayol, and C. Brownson. 2000. The LIM-domain protein FHL1 (SLIM 1) exhibits functional regulation in skeletal muscle. Mol. Cell Biol. Res. Commun. 3:136-140.
38. Lucas, C.A., L.H. Kang, and J.F. Hoh. 2000. Monospecif c antibodies against the three mammalian fast limb myosin heavy chains. Biochem. Biophys. Res. Commun. 272:303-308.
39. Marshall, A., M.S. Salerno, M. Thomas, T. Davies, C. Berry, K. Dyer , J. Bracegirdle, T. Watson, M. Dziadek, R. Kambadur, et al. 2008. Mighty is a novel promyogenic factor in skeletal myogenesis. Exp. Cell Res. 314: 1013-1029.
40. McGrath, M.J., C.A. Mitchell, I.D. Coghill, P.A. Robinson, and S. Brown. 2003. Skeletal muscle LIM protein 1 (SLIM1/FHL1) induces alpha 5 beta 1- integrin-dependent myocyte elongation. Am. J. Physiol. Cell Physiol. 285: C1513-C1526.
41. McGrath, M.J., D.L. Cottle, M.A. Nguyen, J.M. Dyson, I.D. Coghill, P.A. Robinson, M. Holdsworth, B.S. Cowling, E.C. Hardeman, C.A. Mitchell, and S. Brown . 2006 . Four and a half LIM protein 1 binds myosin-binding protein C and regulates myosin f lament formation and sarcomere assembly. J. Biol. Chem. 281:7666-7683.
42. Meredith, S.C. 2005. Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins. Ann. N. Y. Acad. Sci. 1066:181-221.
43. Miniou, P., D. Tiziano, T. Frugier, N. Roblot, M. Le Meur, and J. Melki. 1999. Gene targeting restricted to mouse striated muscle lineage. Nucleic Acids Res. 27:e27.
44. Monticelli, S., and A. Rao. 2002. NFAT1 and NFAT2 are positive regulators of IL-4 gene transcription. Eur. J. Immunol. 32:2971-2978.
45. Morgan, M.J., and A.J. Madgwick. 1999. The LIM proteins FHL1 and FHL3 are expressed differently in skeletal muscle. Biochem. Biophys. Res. Commun. 255:245-250.
46. Morgan, M.J., A.J. Madgwick, B. Charleston, J.M. Pell, and P.T. Loughna. 1995. The developmental regulation of a novel muscle LIM-protein. Biochem. Biophys. Res. Commun. 212:840-846.
47. Musarò, A., and N. Rosenthal. 1999. Maturation of the myogenic program is induced by postmitotic expression of insulin-like growth factor I. Mol. Cell. Biol. 19:3115-3124.
48. Musarò, A., K.J. McCullagh, F.J. Naya, E.N. Olson, and N. Rosenthal. 1999. IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. Nature. 400:581-585.
49. Nair-Shalliker, V. , A.J. Kee, J.E. Joya, C.A. Lucas, J.F. Hoh, and E.C. Hardeman. 2004. Myof ber adaptational response to exercise in a mouse model of nemaline myopathy. Muscle Nerve. 30:470-480.
50. Nakamura,Y.,T.Haneda,J.Osaki,S.Miyata, andK.Kikuchi. 2000. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor. Eur. J. Pharmacol. 391:39-48.
51. Naya, F.J., B. Mercer, J. Shelton, J.A. Richardson, R.S. Williams, and E.N. Olson . 2000 . Stimulation of slow skeletal muscle f ber gene expression by calcineurin in vivo. J. Biol. Chem. 275:4545-4548.
52. O'Connor, R.S., and G.K. Pavlath. 2007. Point:Counterpoint: Satellite cell addition is/is not obligatory for skeletal muscle hypertrophy. J. Appl. Physiol. 103:1099-1100.
53. O'Connor, R.S., S.T. Mills, K.A. Jones, S.N. Ho, and G.K. Pavlath. 2007. A combinatorial role for NFAT5 in both myoblast migration and differentiation during skeletal muscle myogenesis. J. Cell Sci. 120:149-159.
54. Palmer , S. , N. Groves , A. Schindeler , T. Yeoh, C. Biben, C.C. Wang, D.B. Sparrow, L. Barnett, N.A. Jenkins, N.G. Copeland, et al. 2001. The small musclespecif c protein Csl modif es cell shape and promotes myocyte fusion in an Insulin-like growth factor 1-dependent manner. J. Cell Biol. 153:985-998.
55. Parsons, S.A., D.P. Millay , B.J. Wilkins, O.F. Bueno, G.L. Tsika, J.R. Neilson, C.M. Liberatore, K.E. Yutzey, G.R. Crabtree, R.W. Tsika, and J.D. Molkentin . 2004 . Genetic loss of calcineurin blocks mechanical overloadinduced skeletal muscle f ber type switching but not hypertrophy. J. Biol. Chem. 279:26192-26200.
56. Parsons, S.A., D.P. Millay , M.A. Sargent, F.J. Naya, E.M. McNally , H.L. Sweeney, and J.D. Molkentin. 2007. Genetic disruption of calcineurin improves skeletal muscle pathology and cardiac disease in a mouse model of limb-girdle muscular dystrophy. J. Biol. Chem. 282:10068-10078.
57. Patel, K., and F. Muntoni. 2004. Inducing muscle hypertrophy as a therapeutic strategy for muscular dystrophies. 122nd ENMC International Workshop, Naarden, The Netherlands, 28-30 November 2003. Neuromuscul. Disord. 14:519-525.
58. Paul, A.C., and N. Rosenthal . 2002 . Different modes of hypertrophy in skeletal muscle fbers. J. Cell Biol. 156:751-760.
59. Pisconti, A., S. Brunelli, M. Di Padova, C. De Palma, D. Deponti, S. Baesso, V. Sartorelli, G. Cossu, and E. Clementi. 2006. Follistatin induction by nitric oxide through cyclic GMP: a tightly regulated signaling pathway that controls myoblast fusion. J. Cell Biol. 172:233-244.
60. Quinzii, C.M., T.H. Vu, K.C. Min, K. Tanji, S. Barral, R.P. Grewal, A. Kattah, P. Camano, D. Otaegui, T. Kunimatsu, et al. 2008. X-linked dominant scapuloperoneal myopathy is due to a mutation in the gene encoding four-and-a-half-LIM protein 1. Am. J. Hum. Genet. 82:208-213.
61. Rommel, C, S.C. Bodine, B.A. Clarke, R. Rossman, L. Nunez, T.N. Stitt, G.D. Yancopoulos, and D.J. Glass. 2001. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 3:1009-1013.
62. Rosenblatt, J.D., and R.I. Woods. 1992. Hypertrophy of rat extensor digitorum longus muscle injected with bupivacaine. A sequential histochemical, immunohistochemical, histological and morphometric study. J. Anat. 181: 11-27.
63. Sabourin, L.A., A. Girgis-Gabardo, P. Seale, A. Asakura, and M.A. Rudnicki. 1999 . Reduced differentiation potential of primary MyoD-/- myogenic cells derived from adult skeletal muscle. J. Cell Biol. 144:631-643.
64. Sakuma, K., J. Nishikawa, R. Nakao, K. Watanabe, T. Totsuka, H. Nakano, M. Sano, and M. Yasuhara . 2003 . Calcineurin is a potent regulator for skeletal muscle regeneration by association with NFATc1 and GATA-2. Acta Neuropathol. 105:271-280.
65. Sandri, M. 2008. Signaling in muscle atrophy and hypertrophy. Physiology (Bethesda). 23:160-170.
66. Sanger , J.W., P. Chowrashi , N.C. Shaner , S. Spalthoff, J. Wang, N.L. Freeman, and J.M. Sanger. 2002. Myof brillogenesis in skeletal muscle cells. Clin. Orthop. Relat. Res. :S153-S162.
67. Schessl, J., Y. Zou, M.J. McGrath, B.S. Cowling, B. Maiti, S.S. Chin, C. Sewry, R. Battini, Y. Hu, D.L. Cottle, et al. 2008. Proteomic identif cation of FHL1 as the protein mutated in human reducing body myopathy. J. Clin. Invest. 118:904-912.
68. Semsarian, C, P. Sutrave, D.R. Richmond, and R.M. Graham. 1999a. Insulinlike growth factor (IGF-I) induces myotube hypertrophy associated with an increase in anaerobic glycolysis in a clonal skeletal-muscle cell model. Biochem. J. 339:443-451.
69. Semsarian, C, M.J. Wu, YK. Ju, T. Marciniec, T. Yeoh, D.G Allen, R.P Harvey, and R.M. Graham . 1999b . Skeletal muscle hypertrophy is mediated by a Ca2+-dependent calcineurin signalling pathway. Nature. 400:576-581.
70. Shen, T., Y. Liu, Z. Cseresnyes, A. Hawkins, W.R. Randall, and M.F. Schneider. 2006 . Activity- and calcineurin-independent nuclear shuttling of NFATc1, but not NFATc3, in adult skeletal muscle fbers. Mol. Biol. Cell. 17:1570-1582.
71. Shen, X., J.M. Collier , M. Hlaing, L. Zhang, E.H. Delshad, J. Bristow , and H.S. Bernstein . 2003 . Genome-wide examination of myoblast cell cycle withdrawal during differentiation. Dev. Dyn. 226:128-138.
72. St-Pierre, S.J., J.V. Chakkalakal, S.M. Kolodziejczyk, J.C. Knudson, B.J. Jasmin, and L.A. Megeney. 2004. Glucocorticoid treatment alleviates dystrophic myof ber pathology by activation of the calcineurin/NF-AT pathway FASEB J. 18:1937-1939.
73. Stevenson, E.J., A. Koncarevic, PG. Giresi, R.W. Jackman, and S.C. Kandarian. 2005. Transcriptional prof le of a myotube starvation model of atrophy J. Appl. Physiol. 98:1396-1406.
74. Straube, A., and A. Merdes. 2007. EB3 regulates microtubule dynamics at the cell cortex and is required for myoblast elongation and fusion. Curr. Biol. 17:1318-1325.
75. Tinsley, J.M., A.C. Potter, S.R. Phelps, R. Fisher, J.I. Trickett, and K.E. Davies. 1996 . Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature. 384:349-353.
76. Windpassinger, C, B. Schoser , V. Straub, S. Hochmeister , A. Noor , B. Lohberger , N. Farra, E. Petek, T. Schwarzbraun, L. Ofner , et al . 2008. An X-linked myopathy with postural muscle atrophy and generalized hypertrophy, termed XMPMA, is caused by mutations in FHL1. Am. J. Hum. Genet. 82:88-99.
77. Yoshida, N, S. Yoshida, K. Koishi, K. Masuda, and Y. Nabeshima. 1998. Cell heterogeneity upon myogenic differentiation: down-regulation of MyoD and Myf-5 generates 'reserve cells'.J. Cell Sci. 111:769-779.